Showing results (501-510 of 524) with videos related to
Sort By:
Pageof 53
Leukemia|February 5, 2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statementM A Dimopoulos, A Palumbo, M Attal, et al.Leukemia|February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myelomaM A Dimopoulos, X Leleu, A Palumbo, et al.Blood Cancer Journal|April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatmentM A Dimopoulos, A K Stewart, T Masszi, et al.Journal of Internal Medicine|February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial HypertensionS Bringhen, A Milan, M D'Agostino, et al.Leukemia Research|January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II studyJ Thaler, W Hilbe, U Apfelbeck, et al.Leukemia|December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORW-J Chng, H Goldschmidt, M A Dimopoulos, et al.Leukemia|August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyP Moreau, D Joshua, W-J Chng, et al.Leukemia|November 2, 2013
International Myeloma Working Group recommendations for global myeloma careH Ludwig, J S Miguel, M A Dimopoulos, et al.Nature Genetics|December 3, 2003
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosisGeorge Papanikolaou, Mark E Samuels, Erwin H Ludwig, et al.Leukemia|April 23, 2010
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and managementR A Kyle, B G M Durie, S V Rajkumar, et al.Pageof 53